Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prolonging remission with rituximab maintenance therapy.

John D Hainsworth¹

¹Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA.

Seminars in Oncology

|March 26, 2004

Summary

Maintenance therapy with rituximab significantly prolongs remission in patients with indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This approach demonstrated improved response rates and extended progression-free survival with minimal toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.

Cancer discovery·2021

Same author

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).

Clinical breast cancer·2021

Same author

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.

Kidney cancer journal : official journal of the Kidney Cancer Association·2021

Same author

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021

Same author

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021

Area of Science:

Oncology
Immunotherapy
Hematology

Background:

Rituximab is being evaluated for maintenance therapy to extend remission in indolent non-Hodgkin's lymphoma (NHL).
Previous studies suggested potential benefits of rituximab maintenance in B-cell malignancies.

Purpose of the Study:

To assess the efficacy of rituximab maintenance therapy in prolonging remission for indolent NHL and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
To confirm findings from Phase II trials in a randomized Phase III setting.

Main Methods:

Phase II trials investigated rituximab as first-line therapy followed by maintenance in previously untreated indolent NHL and CLL/SLL.
A randomized Phase III trial compared observation versus maintenance rituximab in follicular NHL patients who responded to initial treatment.

Related Experiment Videos

Main Results:

Phase II trials showed improved overall response rates (47% to 73% in NHL) and median progression-free survival (37 months in NHL, 19 months in CLL/SLL).
The Phase III trial demonstrated significantly longer event-free survival in the maintenance rituximab group (23 months vs. 12 months, P =.02).
Maintenance rituximab exhibited minimal toxicity across all trials.

Conclusions:

Maintenance rituximab therapy effectively prolongs remission and improves progression-free survival in indolent NHL and CLL/SLL.
Ongoing trials are exploring optimal schedules, use after combination therapies, and efficacy in other B-cell neoplasms.